Wuhan Easy Diagnosis Biomedicine Co.,Ltd.

Shenzhen Stock Exchange 002932.SZ

Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Net Income Margin for the year ending December 31, 2023: 10.00%

Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Net Income Margin is 10.00% for the year ending December 31, 2023, a -74.99% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Net Income Margin for the year ending December 31, 2022 was 39.97%, a -19.97% change year over year.
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Net Income Margin for the year ending December 31, 2021 was 49.94%, a 2.14% change year over year.
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Net Income Margin for the year ending December 31, 2020 was 48.89%, a 113.29% change year over year.
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Net Income Margin for the year ending December 31, 2019 was 22.92%, a -34.17% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

Shenzhen Stock Exchange: 002932.SZ

Wuhan Easy Diagnosis Biomedicine Co.,Ltd.

CEO	Ms. Chen Li Li
IPO Date	July 10, 2018
Location	China
Headquarters	Wuhan Optics Valley International Biomed
Employees	1,547
Sector	Healthcare
Industries Biotechnology 3D Printing Cleaning Supplies Hardware & Electronics Medical Instruments Personal Care Pharmaceuticals Telehealth

Description

Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of in vitro diagnostic reagents and diagnostic equipment in China and internationally. Its products portfolio includes molecular diagnostic products, such as drug metabolism genetic testing and pathogen nucleic acid detection kits; and immunodiagnostic and blood gas diagnosis products. The company also provides emergency and critical illness information solutions, including information software products, supporting hardware, and certification consulting services; and third-party medical inspection services. It offers products in the areas of cardiovascular, kidney, infectious, diabetes, endocrine and metabolic, obstetrics, and gynecology diseases, as well as prenatal and postnatal care, health checkups, thyroid, hormones, blood gas, coagulation, drug metabolism, pathogen detection. The company was founded in 2008 and is based in Wuhan, China.

Key trends

Past 5 years